SEC Form 4 · accession 0001209191-17-040610
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Farah Champsi
Director
Period of report
Jun 14, 2017
Accepted (ET)
Jun 16, 2017 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 14, 2017 | S | 15,000 | $90.40 | D | 63,664 | D | |
| Common StockF2,F3,F4 | Jun 16, 2017 | S | 5,450 | $88.11 | D | 0 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F2Reflects the transfer from the reporting person to APVIII of 488 shares of the Issuer's common stock on June 1, 2017. The reporting person has been awarded certain restricted stock units in her capacity as a director of the Company (the "RSUs"), and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.